{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:13:26Z","timestamp":1772122406427,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40266-026-01279-9","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:26:49Z","timestamp":1771403209000},"page":"175-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged \u226550 Years with HIV in the United States"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6210-4185","authenticated-orcid":false,"given":"Amanda M.","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2273-1794","authenticated-orcid":false,"given":"Jacqueline","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-9931","authenticated-orcid":false,"given":"Mary J.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3663-9055","authenticated-orcid":false,"given":"Uche","family":"Mordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4977-7819","authenticated-orcid":false,"given":"Daisha","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-9809","authenticated-orcid":false,"given":"Gulce","family":"Askin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-7244","authenticated-orcid":false,"given":"Daniela","family":"Yucuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-7348","authenticated-orcid":false,"given":"Neia Prata","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1662-7329","authenticated-orcid":false,"given":"Travis","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"2","key":"1279_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/QAI.0000000000000960","volume":"72","author":"AEA Siddiqi","year":"2016","unstructured":"Siddiqi AEA, Hall HI, Hu X, Song R. Population-based estimates of life expectancy after HIV diagnosis: United States 2008\u20132011. J Acquir Immune Defic Syndr. 2016;72(2):230\u20136. https:\/\/doi.org\/10.1097\/QAI.0000000000000960.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"1279_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256\u201366. https:\/\/doi.org\/10.1111\/hiv.12421.","journal-title":"HIV Med"},{"key":"1279_CR3","unstructured":"Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas, 2021. 2023. https:\/\/stacks.cdc.gov\/view\/cdc\/149071. Accessed 25 Jan 2025."},{"key":"1279_CR4","unstructured":"HIV.gov. Aging with HIV. 2024. https:\/\/www.hiv.gov\/hiv-basics\/living-well-with-hiv\/taking-care-of-yourself\/aging-with-hiv. Accessed 7 May 2025."},{"key":"1279_CR5","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 17 Oct 2024."},{"issue":"1","key":"1279_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hiv.13319","volume":"24","author":"F Maggiolo","year":"2023","unstructured":"Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age. HIV Med. 2023;24(1):27\u201336. https:\/\/doi.org\/10.1111\/hiv.13319.","journal-title":"HIV Med"},{"issue":"1","key":"1279_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00604-9","volume":"21","author":"S Walmsley","year":"2024","unstructured":"Walmsley S, Smith DE, G\u00f3rgolas M, Cahn PE, Lutz T, Lacombe K, et al. Efficacy and safety of switching to dolutegravir\/lamivudine in virologically suppressed people with HIV-1 aged \u2265 50 years: week 48 pooled results from the TANGO and SALSA studies. AIDS Res Ther. 2024;21(1):17. https:\/\/doi.org\/10.1186\/s12981-024-00604-9.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"1279_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00657-w","volume":"21","author":"JA Manalel","year":"2024","unstructured":"Manalel JA, Kaufman JE, Wu Y, Fusaris E, Correa A, Ernst J, et al. Association of ART regimen and adherence to viral suppression: an observational study of a clinical population of people with HIV. AIDS Res Ther. 2024;21(1):68. https:\/\/doi.org\/10.1186\/s12981-024-00657-w.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"1279_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/09540121.2018.1533232","volume":"31","author":"M Nyaku","year":"2019","unstructured":"Nyaku M, Beer L, Shu F. Non-persistence to antiretroviral therapy among adults receiving HIV medical care in the United States. AIDS Care. 2019;31(5):599\u2013608. https:\/\/doi.org\/10.1080\/09540121.2018.1533232.","journal-title":"AIDS Care"},{"issue":"5","key":"1279_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/13607863.2022.2084504","volume":"27","author":"DD Satre","year":"2023","unstructured":"Satre DD, Sarovar V, Leyden WA, Leibowitz AS, Lam JO, Hojilla JC, et al. Age group differences in substance use, social support, and physical and mental health concerns among people living with HIV two years after receiving primary care-based alcohol treatment. Aging Ment Health. 2023;27(5):1011\u20139. https:\/\/doi.org\/10.1080\/13607863.2022.2084504.","journal-title":"Aging Ment Health"},{"issue":"6","key":"1279_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/apc.2022.0040","volume":"36","author":"B Olivieri-Mui","year":"2022","unstructured":"Olivieri-Mui B, Wilson I, Shi S, Montano M, McCarthy EP, Oh G, et al. Geriatric conditions associated with nonadherence to antiretroviral therapy among older people with HIV: the importance of frailty. AIDS Patient Care STDS. 2022;36(6):226\u201335. https:\/\/doi.org\/10.1089\/apc.2022.0040.","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"1279_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","volume":"9","author":"WF Gellad","year":"2011","unstructured":"Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9(1):11\u201323. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.02.004.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"2","key":"1279_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx070","volume":"4","author":"S Kamal","year":"2017","unstructured":"Kamal S, Locatelli I, Wandeler G, Sehhat A, Bugnon O, Metral M, et al. The presence of human immunodeficiency virus-associated neurocognitive disorders is associated with a lower adherence to combined antiretroviral treatment. Open Forum Infect Dis. 2017;4(2):ofx070. https:\/\/doi.org\/10.1093\/ofid\/ofx070.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"1279_CR14","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1097\/QAD.0000000000003970","volume":"38","author":"MC Masters","year":"2024","unstructured":"Masters MC, Tassiopoulos K, Bao Y, Wu K, Koletar SL, Rubin LH, et al. Risk factors for progression from prediabetes to diabetes among older people with HIV. AIDS. 2024;38(12):1740\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000003970.","journal-title":"AIDS"},{"issue":"11","key":"1279_CR15","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIRCRESAHA.124.323948","volume":"134","author":"K McCutcheon","year":"2024","unstructured":"McCutcheon K, Nqebelele U, Murray L, Thomas TS, Mpanya D, Tsabedze N. Cardiac and renal comorbidities in aging people living with HIV. Circ Res. 2024;134(11):1636\u201360. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323948.","journal-title":"Circ Res"},{"issue":"12","key":"1279_CR16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/infdis\/jix518","volume":"216","author":"J Gallant","year":"2017","unstructured":"Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection\u2014a trend analysis. J Infect Dis. 2017;216(12):1525\u201333. https:\/\/doi.org\/10.1093\/infdis\/jix518.","journal-title":"J Infect Dis"},{"issue":"3","key":"1279_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3851\/IMP3293","volume":"24","author":"MO Halloran","year":"2019","unstructured":"Halloran MO, Boyle C, Kehoe B, Bagkeris E, Mallon P, Post FA, et al. Polypharmacy and drug\u2013drug interactions in older and younger people living with HIV: the POPPY study. Antivir Ther. 2019;24(3):193\u2013201. https:\/\/doi.org\/10.3851\/IMP3293.","journal-title":"Antivir Ther"},{"issue":"3","key":"1279_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s10461-023-04208-8","volume":"28","author":"P Li","year":"2024","unstructured":"Li P, Prajapati G, Geng Z, Ladage VP, Arduino JM, Watson DL, et al. Antiretroviral treatment gaps and adherence among people with HIV in the U.S. Medicare program. AIDS Behav. 2024;28(3):1002\u201314. https:\/\/doi.org\/10.1007\/s10461-023-04208-8.","journal-title":"AIDS Behav"},{"issue":"12","key":"1279_CR19","first-page":"580","volume":"25","author":"JL Priest","year":"2019","unstructured":"Priest JL, Burton T, Blauer-Peterson C, Andrade K, Oglesby A. Clinical characteristics and treatment patterns among US patients with HIV. Am J Manag Care. 2019;25(12):580\u20136.","journal-title":"Am J Manag Care"},{"issue":"12","key":"1279_CR20","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s11606-024-08847-y","volume":"39","author":"JF Figueroa","year":"2024","unstructured":"Figueroa JF, Duggan C, Phelan J, Ang L, Ebem F, Chu J, et al. Antiretroviral therapy use and disparities among Medicare beneficiaries with HIV. J Gen Intern Med. 2024;39(12):2196\u2013205. https:\/\/doi.org\/10.1007\/s11606-024-08847-y.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1279_CR21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/QAD.0000000000003924","volume":"38","author":"A Trickey","year":"2024","unstructured":"Trickey A, Zhang L, Rentsch CT, Pantazis N, Izquierdo R, Antinori A, et al. Care interruptions and mortality among adults in Europe and North America. AIDS. 2024;38(10):1533\u201342. https:\/\/doi.org\/10.1097\/QAD.0000000000003924.","journal-title":"AIDS"},{"issue":"6","key":"1279_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/QAD.0000000000004118","volume":"39","author":"V Pourcher","year":"2025","unstructured":"Pourcher V, Robineau O, Parienti JJ, Loubet P, Palacios C, Jacomet C, et al. Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France. AIDS. 2025;39(6):695\u2013700. https:\/\/doi.org\/10.1097\/QAD.0000000000004118.","journal-title":"AIDS"},{"issue":"1","key":"1279_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-022-00453-4","volume":"19","author":"A Kabarambi","year":"2022","unstructured":"Kabarambi A, Balinda S, Abaasa A, Cogill D, Orrell C. Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa (2002\u20132019). AIDS Res Ther. 2022;19(1):32. https:\/\/doi.org\/10.1186\/s12981-022-00453-4.","journal-title":"AIDS Res Ther"},{"issue":"8","key":"1279_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/hiv.13122","volume":"22","author":"MM Murray","year":"2021","unstructured":"Murray MM, Lin J, Buros Stein A, Wilcox ML, Cottreau J, Postelnick M, et al. Relationship of polypharmacy to HIV RNA suppression in people aged \u226550 years living with HIV. HIV Med. 2021;22(8):742\u20139. https:\/\/doi.org\/10.1111\/hiv.13122.","journal-title":"HIV Med"},{"issue":"6","key":"1279_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","volume":"21","author":"I P\u00e9rez-Valero","year":"2023","unstructured":"P\u00e9rez-Valero I, Corona D, Mart\u00ednez N, L\u00f3pez-Cavanillas M, Lluis C, Luque I. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review. Expert Rev Anti Infect Ther. 2023;21(6):655\u201365. https:\/\/doi.org\/10.1080\/14787210.2023.2203914.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"1279_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67837-6","volume":"14","author":"N Taguchi","year":"2024","unstructured":"Taguchi N, Piao Y, Rubino A, Lee K, Chen M, Harada K, et al. Relationship between adherence to bictegravir\/emtricitabine\/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis. Sci Rep. 2024;14(1):16785. https:\/\/doi.org\/10.1038\/s41598-024-67837-6.","journal-title":"Sci Rep"},{"issue":"4","key":"1279_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, Levy I, D\u2019Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024;25(4):440\u201353. https:\/\/doi.org\/10.1111\/hiv.13593.","journal-title":"HIV Med"},{"issue":"10-11","key":"1279_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/17460794.2024.2403246","volume":"19","author":"A Colson","year":"2024","unstructured":"Colson A, Chastek B, Gruber J, Majethia S, Zachry W, Mezzio D, et al. Persistence in treatment-experienced people with HIV switching anti-retroviral therapy regimens since 2018. Future Virol. 2024;19(10\u201311):371\u201380. https:\/\/doi.org\/10.1080\/17460794.2024.2403246.","journal-title":"Future Virol"},{"issue":"1","key":"1279_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/13696998.2025.2536422","volume":"28","author":"CY Chuo","year":"2025","unstructured":"Chuo CY, Christoph MJ, Zachry W, de Boer M, Chen M, Trom C. Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor-based antiretroviral regimens. J Med Econ. 2025;28(1):1241\u201351. https:\/\/doi.org\/10.1080\/13696998.2025.2536422.","journal-title":"J Med Econ"},{"issue":"1","key":"1279_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107040","volume":"63","author":"A Ciccullo","year":"2024","unstructured":"Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, et al. Comparing the efficacy and safety of a first-line regimen with emtricitabine\/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: results from clinical practice. Int J Antimicrob Agents. 2024;63(1):107040. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107040.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1279_CR31","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1016\/S2352-3018(22)00009-1","volume":"9","author":"J Kiplagat","year":"2022","unstructured":"Kiplagat J, Tran DN, Barber T, Njuguna B, Vedanthan R, Triant VA, et al. How health systems can adapt to a population ageing with HIV and comorbid disease. Lancet HIV. 2022;9(4):e281\u201392. https:\/\/doi.org\/10.1016\/S2352-3018(22)00009-1.","journal-title":"Lancet HIV."},{"issue":"3","key":"1279_CR32","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/s2666-7568(21)00278-6","volume":"3","author":"M Montano","year":"2022","unstructured":"Montano M, Oursler KK, Xu K, Sun YV, Marconi VC. Biological ageing with HIV infection: evaluating the geroscience hypothesis. Lancet Healthy Longev. 2022;3(3):e194-205. https:\/\/doi.org\/10.1016\/s2666-7568(21)00278-6.","journal-title":"Lancet Healthy Longev"},{"key":"1279_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/HIV.S311613","volume":"15","author":"E Frey","year":"2023","unstructured":"Frey E, Johnston CD, Siegler EL. Treatment regimens and care models for older patients living with HIV: are we doing enough? HIV AIDS (Auckl). 2023;15:191\u2013208. https:\/\/doi.org\/10.2147\/HIV.S311613.","journal-title":"HIV AIDS (Auckl)"},{"key":"1279_CR34","doi-asserted-by":"crossref","unstructured":"Elion R, Dunbar M, Rivet Amico K, Gruber J, Harrison L, McComsey GA, et al. Exploring antiretroviral therapy (ART) switch decisions in clinical setting: Trio Health mixed methods study. Presented at: IDWeek; 11\u201315 Oct 2023; Boston, MA, USA. Abstract 1570.","DOI":"10.1093\/ofid\/ofad500.1405"},{"key":"1279_CR35","unstructured":"Sax P, Eron J, Radtchenko J, Dunbar M, Gruber J, Fridman M, et al. What influences switching to DTG\/3TC vs B\/F\/TAF in clinical practice? Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI); 19\u201322 Feb 2023; Seattle, WA, USA. Poster 532."},{"key":"1279_CR36","unstructured":"KFF. Health coverage by race and ethnicity, 2010\u20132023. 2025. https:\/\/www.kff.org\/racial-equity-and-health-policy\/issue-brief\/health-coverage-by-race-and-ethnicity. Accessed 9 Apr 2025."},{"issue":"8","key":"1279_CR37","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/10815589231182313","volume":"71","author":"R Mathai","year":"2023","unstructured":"Mathai R, Hinestrosa F, DeJesus E, Rolle CP. Racial\/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic. J Investig Med. 2023;71(8):946\u201352. https:\/\/doi.org\/10.1177\/10815589231182313.","journal-title":"J Investig Med"},{"issue":"5","key":"1279_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/QAI.0000000000003214","volume":"93","author":"JL Raiford","year":"2023","unstructured":"Raiford JL, Yuan X, Carree T, Beer L. Understanding disparities in antiretroviral therapy adherence and sustained viral suppression among Black, Hispanic\/Latina, and White women in the United States \u2013 Medical Monitoring Project, United States, 2015\u20132019. J Acquir Immune Defic Syndr. 2023;93(5):413\u201321. https:\/\/doi.org\/10.1097\/QAI.0000000000003214.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01279-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:31:34Z","timestamp":1772119894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01279-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1279"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01279-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amanda M. Kong, Jacqueline Lucia, Daisha Joseph, Gulce Askin, and Daniela Yucuma are employees of and may own stock or stock options in Aetion, Inc., which received funding from Gilead Sciences, Inc., to conduct this analysis. Mary J. Christoph, Uche Mordi, Neia Prata Menezes, Peter McMahon, and Travis Lim are employees of and may own stock or stock options in Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The dataset generated during the current study is not publicly available as it is a proprietary dataset.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study used retrospectively collected data and received a formal institutional review board exemption. Data contained no personal identification fields.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this was a secondary analysis of existing data, informed consent was not obtained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: Mary J. Christoph, Uche Mordi, and Travis Lim. Methodology: Amanda M. Kong, Jacqueline Lucia, Mary J. Christoph, Uche Mordi, Daisha Joseph, Gulce Askin, Daniela Yucuma, and Travis Lim. Formal analysis: Amanda M. Kong, Jacqueline Lucia, Daisha Joseph, Gulce Askin, and Daniela Yucuma. Data curation: Amanda M. Kong, Jacqueline Lucia, Daisha Joseph, Gulce Askin, and Daniela Yucuma. Writing \u2013 review and editing: Amanda M. Kong, Jacqueline Lucia, Mary J. Christoph, Uche Mordi, Daisha Joseph, Gulce Askin, Daniela Yucuma, Neia Prata Menezes, Peter McMahon, and Travis Lim. Supervision: Travis Lim. Project administration: Travis Lim. All authors have read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}